Forest Replants Combunox Sales Force For Pending Beta-Blocker Nebivolol
Executive Summary
Forest's plans to distinguish its marketed antihypertensive Benicar and the pending nebivolol include detailing the two products with separate sales forces
You may also be interested in...
Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups
Forest has already started conducting postmarketing studies for its antihypertensive nebivolol - in advance of the product's approval - "to further highlight potential differences from existing beta blockers," according to Investor Relations VP Charles Triano
Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups
Forest has already started conducting postmarketing studies for its antihypertensive nebivolol - in advance of the product's approval - "to further highlight potential differences from existing beta blockers," according to Investor Relations VP Charles Triano
Forest’s Namenda Combo Use Rises With Part D, Patent Expirations Loom
Forest is seeing a strong uptick in combination use of its Alzheimer's therapy Namenda (memantine) as a result of favorable Medicare Part D coverage